{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:07:53Z","timestamp":1794244073346,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40119-025-00424-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T15:29:27Z","timestamp":1752938967000},"page":"385-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1007","volume":"14","author":[{"given":"Emily","family":"Margolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily K.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Argiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Urey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-3691","authenticated-orcid":false,"given":"Kevin M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","DOI":"10.36660\/ijcs.20240112","volume":"37","author":"MV Sim\u00f5es","year":"2024","unstructured":"Sim\u00f5es MV, Fernandes F, Dabarian A, Valicelli FH, Mesquita CT. Evolving therapies for transthyretin cardiac amyloidosis: new clinical trials with amyloid fibrils depleter. Int J Cardiovasc Sci. 2024;37: e20240112. https:\/\/doi.org\/10.36660\/ijcs.20240112.","journal-title":"Int J Cardiovasc Sci"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"1154594","DOI":"10.3389\/fcvm.2023.1154594","volume":"10","author":"D Tomasoni","year":"2023","unstructured":"Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, Lombardi CM, Nardi M, Pagnesi M, Riccardi M, Vergaro G, Vizzardi E, Emdin M, Metra M. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. Front Cardiovasc Med. 2023;10:1154594. https:\/\/doi.org\/10.3389\/fcvm.2023.1154594.","journal-title":"Front Cardiovasc Med"},{"key":"424_CR3","unstructured":"Wasfy JH, Winn AN, Touchette DR, Nikitin D, Shah KK, Richardson M, Lee W, Kim S, Rind DM. Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy; draft evidence report. Institute for Clinical and Economic Review, July 17, 2024."},{"issue":"4","key":"424_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"J Griffin","year":"2021","unstructured":"Griffin J, Rosenthal J, Grodin J, et al. ATTR amyloidosis: current and emerging management strategies: JACC: cardiooncology state-of-the-art review. J Am Coll Cardiol CardioOnc. 2021;3(4):488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006.","journal-title":"J Am Coll Cardiol CardioOnc"},{"key":"424_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/phar.4639","author":"EL Hellenbart","year":"2024","unstructured":"Hellenbart EL, Ipema HJ, Rodriguez-Ziccardi MC, Krishna H, DiDomenico RJ. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications. Pharmacotherapy. 2024. https:\/\/doi.org\/10.1002\/phar.4639.","journal-title":"Pharmacotherapy"},{"key":"424_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/hci.0000000000000029","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, et al. ASNC\/AHA\/ase\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2\u2014evidence base and standardized methods of imaging. Circulation Cardiovasc Imaging. 2021. https:\/\/doi.org\/10.1161\/hci.0000000000000029.","journal-title":"Circulation Cardiovasc Imaging"},{"issue":"30","key":"424_CR7","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1093\/eurheartj\/ehx740","volume":"39","author":"A Singh","year":"2018","unstructured":"Singh A, Falk RH. \u2018A new staging system for cardiac transthyretin amyloidosis\u2019: is it already on the verge of obsolescence? Eur Heart J. 2018;39(30):2807\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehx740.","journal-title":"Eur Heart J"},{"key":"424_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000792","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, et al. Cardiac amyloidosis: evolving diagnosis and management: A scientific statement from the American Heart Association. Circulation. 2020. https:\/\/doi.org\/10.1161\/cir.0000000000000792.","journal-title":"Circulation"},{"issue":"10","key":"424_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034518","volume":"13","author":"N Kuyama","year":"2024","unstructured":"Kuyama N, Takashio S, Oguni T, Yamamoto M, Hirakawa K, Ishii M, Hanatani S, Oda S, Matsuzawa Y, Usuku H, Yamamoto E, Hirai T, Ueda M, Tsujita K. Cardiac biomarker change at 1 year after tafamidis treatment and clinical outcomes in patients with transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2024;13(10): e034518. https:\/\/doi.org\/10.1161\/JAHA.124.034518.","journal-title":"J Am Heart Assoc"},{"key":"424_CR10","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s12325-024-02891-0","volume":"41","author":"MS Maurer","year":"2024","unstructured":"Maurer MS, Soman P, Hernandez A, et al. Advancing transthyretin amyloidosis drug development in an evolving treatment landscape: amyloidosis forum meeting proceedings. Adv Ther. 2024;41:2723\u201342. https:\/\/doi.org\/10.1007\/s12325-024-02891-0.","journal-title":"Adv Ther"},{"key":"424_CR11","doi-asserted-by":"publisher","unstructured":"Fontana M, et al. \u201cThe last decade in cardiac amyloidosis.\u201d JACC: Cardiovasc Imaging. 2025, https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011.","DOI":"10.1016\/j.jcmg.2024.10.011"},{"issue":"11","key":"424_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/nejmoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/nejmoa1805689.","journal-title":"New Engl J Med"},{"issue":"Suppl. 2","key":"424_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.2115","volume":"41","author":"C Rapezzi","year":"2020","unstructured":"Rapezzi C, Kristen V, Gundapaneni B, Sultan MB, Hanna M. Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy. Eur Heart J. 2020;41(Suppl. 2): ehaa946.2115. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.2115.","journal-title":"Eur Heart J"},{"issue":"2","key":"424_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/nejmoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, et al. Efficacy and safety of ACORAMIDIS in transthyretin amyloid cardiomyopathy. New England J Med. 2024;390(2):132\u201342. https:\/\/doi.org\/10.1056\/nejmoa2305434.","journal-title":"New England J Med"},{"issue":"17","key":"424_CR15","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/nejmoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. New England J Med. 2023;389(17):1553\u201365. https:\/\/doi.org\/10.1056\/nejmoa2300757.","journal-title":"New England J Med"},{"issue":"1","key":"424_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/nejmoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. New England J Med. 2025;392(1):33\u201344. https:\/\/doi.org\/10.1056\/nejmoa2409134.","journal-title":"New England J Med"},{"key":"424_CR17","first-page":"16","volume":"2024","author":"A Murad","year":"2024","unstructured":"Murad A. A Phase 1, single ascending dose study to evaluate ALN-TTRsc04, a next-generation RNA interference therapeutic, in healthy participants for potential treatment of transthyretin amyloidosis. Am Heart Assoc Sci Sess. 2024;2024:16\u20138.","journal-title":"Am Heart Assoc Sci Sess"},{"key":"424_CR18","unstructured":"\u201cAlnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day.\u201d BioSpace, Alnylam Pharmaceuticals, 25 Feb. 2025, www.biospace.com\/press-releases\/alnylam-highlights-significant-pipeline-progress-and-platform-innovation-at-r-d-day."},{"issue":"23","key":"424_CR19","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/nejmoa2412309","volume":"391","author":"M Fontana","year":"2024","unstructured":"Fontana M, Solomon SD, et al. CRISPR-Cas9 gene editing with Nexiguran Ziclumeran for ATTR cardiomyopathy. New Engl J Med. 2024;391(23):2231\u201341. https:\/\/doi.org\/10.1056\/nejmoa2412309.","journal-title":"New Engl J Med"},{"key":"424_CR20","unstructured":"\u201cMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM).\u201d Clinicaltrials.Gov, National Cancer Institute, clinicaltrials.gov\/study\/NCT06128629?intr=NCT06128629&rank=1."},{"key":"424_CR21","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon A, Hagenbuch A, Huy C, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12:3142.","journal-title":"Nat Commun"},{"key":"424_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11886-024-02172-w","volume":"27","author":"AGM Patel","year":"2025","unstructured":"Patel AGM, Li P, Badrish N, et al. Transthyretin cardiac amyloidosis: current and emerging therapies. Curr Cardiol Rep. 2025;27:33. https:\/\/doi.org\/10.1007\/s11886-024-02172-w.","journal-title":"Curr Cardiol Rep"},{"key":"424_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae811","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez E, et al. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehae811.","journal-title":"Eur Heart J"},{"key":"424_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2024.2420809","author":"OB Suhr","year":"2024","unstructured":"Suhr OB, Grogan M, da Silva AM, Karam C, Garcia-Pavia P, Drachman B, Kinney GG. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid. 2024. https:\/\/doi.org\/10.1080\/13506129.2024.2420809.","journal-title":"Amyloid"},{"issue":"3","key":"424_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/nejmoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. New Engl J Med. 2023;389(3):239\u201350. https:\/\/doi.org\/10.1056\/nejmoa2303765.","journal-title":"New Engl J Med"},{"issue":"31","key":"424_CR26","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"Ioannou","year":"2023","unstructured":"Ioannou, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, Jiang A, Cabras G, Filisetti S, Bolhuis RE, Bandera F, Venneri L, Martinez-Naharro Ana, Law S, Kotecha T, Virsinskaite R, Knight DS, Emdin M, Petrie A, Lachmann H, Wechelakar A, Petrie M, Hughes A, Freemantle N, Hawkins PN, Whelan C, McMurray JJV, Gillmore JD, Fontana M. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44(31):2893\u2013907. https:\/\/doi.org\/10.1093\/eurheartj\/ehad347.","journal-title":"Eur Heart J"},{"issue":"1","key":"424_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/13506129.2024.2431082","volume":"32","author":"E Cabrera-Romero","year":"2025","unstructured":"Cabrera-Romero E, Serrao-Faria LA, Mora-Ayestar\u00e1n N, Peir\u00f3-Avent\u00edn B, Espinoza A, de Castro D, Cobo-Marcos M, Dom\u00ednguez F, Gonz\u00e1lez-L\u00f3pez E, Garcia-Pavia P. Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy. Amyloid. 2025;32(1):87\u20139. https:\/\/doi.org\/10.1080\/13506129.2024.2431082. (Epub 2024 Nov 20 PMID: 39565050).","journal-title":"Amyloid"},{"issue":"11","key":"424_CR28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. J Am Coll Cardiol. 2023;81(11):1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol"},{"key":"424_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001063","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines\u201d. Circulation. 2022. https:\/\/doi.org\/10.1161\/cir.0000000000001063.","journal-title":"Circulation"},{"issue":"24","key":"424_CR30","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411\u201322. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.429.","journal-title":"J Am Coll Cardiol"},{"key":"424_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","volume":"84","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Fumagalli C, Razvi Y, et al. Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2024;84:43\u201358.\u00a0https:\/\/doi.org\/10.1016\/j.jacc.2024.04.011.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"424_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","volume":"2","author":"RK Cheng","year":"2020","unstructured":"Cheng RK, et al. \u201cDiuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC: CardioOncology. 2020;2(3):414\u201324. https:\/\/doi.org\/10.1016\/j.jaccao.2020.06.007.","journal-title":"JACC: CardioOncology"},{"issue":"9","key":"424_CR33","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","volume":"6","author":"Eoin Donnellan","year":"2020","unstructured":"Donnellan Eoin, et al. Atrial fibrillation in transthyretin cardiac amyloidosis. JACC: Clin Electrophysiol. 2020;6(9):1118\u201327. https:\/\/doi.org\/10.1016\/j.jacep.2020.04.019.","journal-title":"JACC: Clin Electrophysiol"},{"issue":"6","key":"424_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14308","volume":"35","author":"GN Vaidya","year":"2021","unstructured":"Vaidya GN, Patel JK, Kittleson M, Chang DH, Kransdorf E, Geft D, Czer L, Vescio R, Esmailian F, Kobashigawa JA. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant. 2021;35(6): e14308. https:\/\/doi.org\/10.1111\/ctr.14308. (Epub 2021 Apr 19 PMID: 33825224).","journal-title":"Clin Transplant"},{"issue":"6","key":"424_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","volume":"8","author":"CD Barrett","year":"2020","unstructured":"Barrett CD, Alexander KM, Zhao H, Haddad F, Cheng P, Liao R, Wheeler MT, Liedtke M, Schrier S, Arai S, Weisshaar D, Witteles RM. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC Heart Fail. 2020;8(6):461\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.013. (Epub 2020 May 6 PMID: 32387068).","journal-title":"JACC Heart Fail"},{"key":"424_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.70070","author":"MA Lyle","year":"2025","unstructured":"Lyle MA, et al. Amyloidosis and heart transplantation in a new era. Clin Transpl. 2025. https:\/\/doi.org\/10.1111\/ctr.70070.","journal-title":"Clin Transpl"},{"issue":"6","key":"424_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23(6):895\u2013905. https:\/\/doi.org\/10.1002\/ejhf.2198.","journal-title":"Eur J Heart Fail"},{"key":"424_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3540","author":"L Zeldin","year":"2024","unstructured":"Zeldin L, Eichler JBS, Teruya SL, Weinsaft AY, Mirabal A, Cuomo MO, Mateo K, Helmke S, Maurer MS. Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3540. (Epub ahead of print. PMID: 39638976).","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"424_CR39","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jacc.2024.10.097","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, et al. Worsening of heart\u00a0failure in outpatients with transthyretin amyloidosis and cardiomyopathy in the Apollo-B trial. J Am Coll Cardiol. 2025;85(7):744\u201352. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.097.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"424_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","volume":"85","author":"M Fontana","year":"2025","unstructured":"Fontana M, Maurer MS, Gillmore JD, Bender S, Aldinc E, Eraly SA, Jay PY, Solomon SD. Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B Trial. J Am Coll Cardiol. 2025;85(7):753\u201361. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.015. (Epub 2024 Nov 18 PMID: 39566871).","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"424_CR41","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"424_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/heartjnl-2021-319063","volume":"108","author":"S Law","year":"2021","unstructured":"Law S, et al. Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart. 2021;108(6):474\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2021-319063.","journal-title":"Heart"},{"key":"424_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ehf2.12203","volume":"5","author":"S Takashio","year":"2018","unstructured":"Takashio S, et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Fail. 2018;5:27\u201335.","journal-title":"ESC Heart Fail"},{"issue":"21","key":"424_CR44","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.3390\/jcm10214868","volume":"10","author":"S Oghina","year":"2021","unstructured":"Oghina S, et al. Prognostic Value of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T levels in the natural history of transthyretin amyloid cardiomyopathy and their evolution after tafamidis treatment. J Clin Med. 2021;10(21):4868. https:\/\/doi.org\/10.3390\/jcm10214868.","journal-title":"J Clin Med"},{"key":"424_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.117.004000","author":"JLS Hanson","year":"2018","unstructured":"Hanson JLS, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circulation Heart Fail. 2018. https:\/\/doi.org\/10.1161\/circheartfailure.117.004000.","journal-title":"Circulation Heart Fail"},{"issue":"4","key":"424_CR46","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.2824","volume":"25","author":"A Aimo","year":"2023","unstructured":"Aimo A, Tomasoni D, Porcari A, Vergaro G, Castiglione V, Passino C, et al. Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. Eur J Heart Fail. 2023;25(4):510\u20133. https:\/\/doi.org\/10.1002\/ejhf.2824.","journal-title":"Eur J Heart Fail"},{"key":"424_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2169\/internalmedicine.49.2703","volume":"49","author":"M Takigawa","year":"2010","unstructured":"Takigawa M, Hashimura K, Ishibashi-Ueda H, Yamada N, Kiso K, Nanasato M, Yoshida Y, Hirayama H. Annual electrocardiograms consistent with silent progression of cardiac involvement in sporadic familial amyloid polyneuropathy: a case report. Intern Med. 2010;49:139\u201344.\u00a0https:\/\/doi.org\/10.2169\/internalmedicine.49.2703.","journal-title":"Intern Med"},{"issue":"22","key":"424_CR48","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"F Ruberg","year":"2019","unstructured":"Ruberg F, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. JACC. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"JACC"},{"key":"424_CR49","unstructured":"ATTRUBY (acoramidis) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf. November 2024."},{"issue":"15","key":"424_CR50","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, NEURO-TTRansform Investigators, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358. https:\/\/doi.org\/10.1001\/jama.2023.18688.","journal-title":"JAMA"},{"issue":"Supplement_1","key":"424_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.2088","volume":"45","author":"M Maurer","year":"2024","unstructured":"Maurer M, Cappelli F, Fontana M, Garcia-Pavia P, Grogan M, Hanna M, Judge D, Masri A, Du J, Siddhanti S, Tamby J, Ji A, Sinha U, Fox J, Gilmore J, ATTRibute \u2013 CM Study Group and Open-Label Extension Study Group. Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension. Eur Heart J. 2024;45(Supplement_1): ehae666.2088. https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.2088.","journal-title":"Eur Heart J"},{"key":"424_CR52","unstructured":"\u201cAdditional Data Showing Acoramidis Increases Serum Transthyretin Which Is Associated with Improved Cardiovascular Outcomes Presented at ISA from Bridgebio Pharma\u2019s Phase 3 Attribute-Cm Study in Transthyretin Amyloid Cardiomyopathy (ATTR-Cm).\u201d GlobeNewswire News Room, BridgeBio Pharma, Inc., 29 May 2024, www.globenewswire.com\/news-release\/2024\/05\/29\/2890251\/0\/en\/Additional-Data-Showing-Acoramidis-Increases-Serum-Transthyretin-Which-is-Associated-with-Improved-Cardiovascular-Outcomes-Presented-at-ISA-from-BridgeBio-Pharma-s-Phase-3-ATTRibut.html."},{"key":"424_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-024-03198-7","volume":"19","author":"TN Qarni","year":"2024","unstructured":"Qarni TN, Jones FJS, Drachman B, et al. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study. Orphanet J Rare Dis. 2024;19:191. https:\/\/doi.org\/10.1186\/s13023-024-03198-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"424_CR54","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/CIRCULATIONAHA.123.067225","volume":"149","author":"R Pedretti","year":"2024","unstructured":"Pedretti R, Wang L, Hanna M, Benson MD, Grodin JL, Tang WHW, Masri A, Saelices L. Detection of circulating transthyretin amyloid aggregates in plasma: a novel biomarker for transthyretin amyloidosis. Circulation. 2024;149(21):1696\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067225.","journal-title":"Circulation"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00424-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:21:06Z","timestamp":1757258466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00424-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00424-6","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emily Margolin, MD, and Alessia Argiro, MD, have nothing to disclose. Lily Stern, MD, has received research grants from Intellia Therapeutics and Pfizer. Julie Rosenthal, MD, has received consulting fees from BridgeBio and Novo Nordisk, and research funding for clinical studies from Novo Nordisk, Ionis, and Alnylam. Marcus Urey, MD, has received consulting fees from Alnylam, AstraZeneca, BridgeBio, Pfizer, and research funding for clinical studies from Alexion, Intellia, and Ionis. Kevin Alexander, MD, has received consulting fees from Alexion, Alnylam, Arbor Biotechnologies, Bridgebio, Novo Nordisk, and Pfizer. Kevin Alexander, MD, is an Editorial Board member of Cardiology and Therapy. Kevin Alexander was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}